EMA Authorised: Alymsys (bevacizumab) — Mabxience Research SL

View source ↗

Summary

The EMA authorised Alymsys, a bevacizumab biosimilar from Mabxience Research SL. It is approved for multiple cancer indications including colorectal, breast, ov…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cervical Cancer
• Colorectal Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Peritoneal Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Alymsys (bevacizumab)

Snippet

Status: Authorised. Therapeutic area: Colorectal Neoplasms;Breast Neoplasms;Ovarian Neoplasms;Peritoneal Neoplasms;Carcinoma, Non-Small-Cell Lung;Carcinoma, Renal Cell;Uterine Cervical Neoplasms. MAH: Mabxience Research SL. Decision date: 06/02/2026